DTU Logo
Publications | Conference abstracts | Slidesets | Webcasts

Publications (30 of 431)

Search Publications :

In-press or Epub

Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis
Abderrahim Oulhaj, Anouar El Ghouch and Rury R Holman
Stat Methods Med Res. 2017. Epub:03-Jul-2017. PMID:28670972. doi:10.1177/0962280217717761


Baseline Characteristics and Temporal Differences in Acarbose Cardiovascular Evaluation (ACE) Trial Participants
Michael J. Theodorakis, Ruth L. Coleman, Huimei Feng, Juliana Chan, Jean-Louis Chiasson, Junbo Ge, Hertzel C. Gerstein, Yong Huo, Zhihui Lang, John J. McMurray, Lars Rydén, Stefan Schröder, Michal Tendera, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan and Rury R. Holman for the ACE Study Group
Am Heart J 2017;199:170-175. Published:May-2018. Epub:10-Sep-2017. PMID:29754657. doi:10.1016/j.ahj.2017.09.001

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel, Rishi A. Patel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Robert J. Mentz, Neha J. Pagidipati, Juliana C. Chan, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Peter Öhman, Neil R. Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez, and Rury R. Holman, for the EXSCEL Study Group
Lancet Diabetes Endocrinol. 2017;6:105-113. Published:Feb-2018. Epub:06-Dec-2017. PMID:29221659. doi:10.1016/S2213-8587(17)30412-6

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes – Authors' reply
Rury R. Holman, M. Angelyn Bethel, Adrian F. Hernandez,
N Eng J Med 2017;377:2502. Published:21-Dec-2017. PMID:29262286. doi:10.1056/NEJMc1714163

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial
Abhinav Sharma, Jennifer B. Green, Allison Dunning, Yuliya Lokhnygina, Sana M. Al-Khatib, Renato D. Lopes, John B. Buse, John M. Lachin, Frans Van de Werf, Paul W. Armstrong, Keith D. Kaufman, Eberhard Standl, Juliana C.N. Chan, Larry A. Distiller, Russell Scott, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
Diabetes Care 2017;40:1763-1770. Published:Dec-2017. Epub:06-Oct-2017. PMID:28986504. doi:10.2337/dc17-1091

Health selection into neighborhoods among patients enrolled in a clinical trial
Mariana Arcaya, Ruth L. Coleman, Fahad Razak, Maria L. Alva, Rury R. Holman
Preventive Medicine Reports 2017;8:51–54. Published:Dec-2017. Epub:28-Jul-2017. PMID:28924547. doi:10.1016/j.pmedr.2017.07.003

Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A Randomised Controlled Trial
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan for the ACE Study Group
Lancet Diabetes Endocrinol. 2017;5:877-86. Published:Nov-2017. Epub:13-Sep-2017. PMID:28917545. doi:10.1016/S2213-8587(17)30309-1
[Slides] [Slides #2]

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED
Hypertension 2017;70:907-914. Published:Nov-2017. Epub:28-Aug-2017. PMID:28847886. doi:10.1161/HYPERTENSIONAHA.117.09482

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS
Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group
Diabetes Obes Metab. 2017;19:1587–1593. Published:Nov-2017. Epub:22-Apr-2017. PMID:28432745. doi:10.1111/dom.12983

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis
Rakesh Malhotra, Hoang Anh Nguyen, Oscar Benavente, Mihriye Mete, Barbara Howard, Jonathan Mant, Michelle C. Odden, Carmen A. Peralta, Alfred Cheung, Girish Nadkarni, Ruth L. Coleman, Rury R. Holman, Alberto Zanchetti, Ruth Peters, Nigel Beckett, Jan Staessen, Joachim H. Ix
JAMA Intern Med 2017;177:1498-1505. Published:Oct-2017. Epub:05-Sep-2017. PMID:28873137. doi:10.1001/jamainternmed.2017.4377

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, and Adrian F. Hernandez, for the EXSCEL Study Group
N Engl J Med 2017;377:1228-39. Published:28-Sep-2017. Epub:14-Sep-2017. PMID:28910237. doi:10.1056/NEJMoa1612917

Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International 2 Insights from the TECOS Trial
Neha J. Pagidipati, Ann Marie Navar, Karen S. Pieper, Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, Robert G. Josse, Darren K. McGuire, Yuliya Lokhnygina, Jan H. Cornel, Sigrun Halvorsen, Timo E. Strandberg, Tuncay Delibasi, Rury R. Holman, Eric D. Peterson, On behalf of the TECOS Study Group
Circulation 2017;136:1193–1203. Published:26-Sep-2017. Epub:16-Jun-2017. PMID:28626088. doi:10.1161/CIRCULATIONAHA.117.027252

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Robert J. Mentz , M. Angelyn Bethel, Stephanie Gustavson, Vivian P. Thompson, Neha J. Pagidipati, John B. Buse, Juliana C. Chan, Nayyar Iqbal, Aldo P. Maggioni, Steve P. Marso, Peter Ohman, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez, Rury R. Holman
Am Heart J. 2017;187:1-9. Published:14-Sep-2017. Epub:12-Feb-2017. PMID:28454792. doi:10.1016/j.ahj.2017.02.005

Do Glycoalbumin Levels Preferentially Reflect Changes in Postprandial Glucose Excursions?
S. K. Paul and R. R. Holman
Diabetic Medicine 2017;34:1284–1290. Published:Sep-2017. Epub:13-Jun-2017. PMID:28477414. doi:10.1111/dme.13376

Continuous Glucose Monitoring Detected Hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T)
JC Levy, MJ Davies, RR Holman, for the 4-T Study Group
Diabetes Res Clin Pract. 2017;131:161–168. Published:Sep-2017. Epub:21-Mar-2017. PMID:28750219. doi:10.1016/j.diabres.2017.01.022

Metformin – 60 years of clinical experience
Ed. Ian W Campbell, Harry CS Howlett, Rury R Holman, Clifford J Bailey
ISBN 978-3-527-34449-9 2017;1-122. Published:Sep-2017

Microvascular outcomes in type 2 diabetes - Authors' reply
Sophia Zoungas, Hertzel C Gerstein, Rury R Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L Coleman, John Chalmers, the Collaborators on Trials of Lowering Glucose (CONTROL) writing group
Lancet Diabetes Endocrinol 2017;5:580. Published:Aug-2017. PMID:28732664. doi:10.1016/S2213-8587(17)30185-7

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
Lancet Diabetes Endocrinol. 2017;5:431-437. Published:Jun-2017. Epub:29-Mar-2017. PMID:28365411. doi:10.1016/S2213-8587(17)30104-3

Corrections needed to 2016 ESC and AHA guidelines on heart failure
Lars Rydén, Frans Van de Werf, Paul W Armstrong, Darren K McGuire, Eberhard Standl, Eric D Peterson, Rury R Holman
Lancet Diabetes Endocrinol. 2017;5:325-326. Published:May-2017. Epub:05-Apr-2017. PMID:28395875. doi:10.1016/S2213-8587(17)30102-X

Updated risk factors should be used to predict development of diabetes
Mary Angelyn Bethel, Kristen A. Hyland, Antonio R. Chacra, Prakash Deedwania, Gregory R. Fulcher, Rury R. Holman, Trond Jenssen, Naomi S. Levitt, John J.V. McMurray, Eleni Boutati, Laine Thomas, Jie-Lena Sun, Steven M. Haffner for the NAVIGATOR Study Group
J Diabetes Complications 2017;31:859-863. Published:May-2017. Epub:02-Mar-2017. PMID:28319004. doi:10.1016/j.jdiacomp.2017.02.012

Effect of gonadotropin inhibitory hormone (GnIH) on luteinizing hormone secretion in humans
George JT, Hendrikse M, Veldhuis JD, Clarke IJ, Anderson RA, Millar RP
Clin Endocrinol (Oxf). 2017;86:731-738. Published:May-2017. Epub:10-Feb-2017. PMID:28186349. doi:10.1111/cen.13308

Letter regarding AHA Scientific Statement “Drugs That May Cause or Exacerbate Heart Failure.”
Peterson ED, Armstrong PW, Holman RR
AHA website 2017;1. Published:Apr-2017. Epub:27-Apr-2017
[Full text]

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)
M. Angelyn Bethel, Samuel S. Engel, Jennifer B. Green, Zhen Huang, Robert G. Josse, Keith D. Kaufman, Eberhard Standl, Shailaja Suryawanshi, Frans Van de Werf, Darren K. McGuire, Eric D. Peterson, Rury R. Holman, for the TECOS Study Group
Diabetes Care 2017;40:494–501. Published:Apr-2017. Epub:05-Jan-2017. PMID:28057693. doi:10.2337/dc16-1135

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial
Sharma A, de Souza Brito F2, Sun JL, Thomas L, Haffner S, Holman RR, Lopes RD
Am Heart J. 2017;186:73-82. Published:Apr-2017. Epub:29-Dec-2016. PMID:28454835. doi:10.1016/j.ahj.2016.12.011

Sustained influence of metformin therapy on circulating GLP-1 levels in individuals with and without type 2 diabetes
Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, Hansen TH; DIRECT consortium, Stewart MC, Holman RR, Franks PW, Walker M, Pearson ER, Sattar N
Diabetes Obes Metab. 2017;19:356–363. Published:Mar-2017. Epub:13-Nov-2016. PMID:278628. doi:10.1111/dom.12826

Modeling the oral glucose tolerance test in normal and impaired glucose tolerant states: a population approach
Theodorakis MJ, Katsiki N, Arampatzi K, Chrousos GP
Curr Med Res Opin. 2017;33:305-313. Published:Feb-2017. Epub:31-Dec-2016. PMID:27794624. doi:10.1080/03007995.2016.1254607

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance
Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, Lopes RD
J Am Heart Assoc 2017;6:e003892. Published:13-Jan-2017. Epub:13-Jan-2017. PMID:28087508. doi:10.1161/JAHA.116.003892

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance
Currie G, Angelyn Bethel M, Holzhauer B, Haffner SM, Holman RR, McMurray JJ
Diabetes Obes Metab. 2017;19:791-799. Epub:17-Jul-2017. PMID:28093841. doi:10.1111/dom.12877

Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management
Katsiki N, Mikhailidis DP, Theodorakis MJ
Curr Pharm Des. 2017;23:1522-1532. Epub:13-Jan-2017. PMID:28088910. doi:10.2174/1381612823666170113152742